RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC
- DOI
- 10.1016/j.jtocrr.2025.100912
- Published
- 2025-12
- Container
- JTO Clinical and Research Reports
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.jtocrr.2025.100912,
title = {RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC},
author = {Makoto Nishio and Takashi Seto and Martin Reck and Edward B. Garon and Kazuto Nishio and Kazuo Kasahara and Kazumi Nishino and Miyako Satouchi and Kiyotaka Yoh and Hidetoshi Hayashi and Kazuko Sakai and Sotaro Enatsu and Tomoko Matsui and Sunoj Chacko Varughese and Michelle Carlsen and Carla Visseren-Grul and Kazuhiko Nakagawa},
year = {2025},
journal = {JTO Clinical and Research Reports},
doi = {10.1016/j.jtocrr.2025.100912},
url = {https://doi.org/10.1016/j.jtocrr.2025.100912}
}RIS
TY - JOUR TI - RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC AU - Makoto Nishio AU - Takashi Seto AU - Martin Reck AU - Edward B. Garon AU - Kazuto Nishio AU - Kazuo Kasahara AU - Kazumi Nishino AU - Miyako Satouchi AU - Kiyotaka Yoh AU - Hidetoshi Hayashi AU - Kazuko Sakai AU - Sotaro Enatsu AU - Tomoko Matsui AU - Sunoj Chacko Varughese AU - Michelle Carlsen AU - Carla Visseren-Grul AU - Kazuhiko Nakagawa PY - 2025 JO - JTO Clinical and Research Reports DO - 10.1016/j.jtocrr.2025.100912 UR - https://doi.org/10.1016/j.jtocrr.2025.100912 ER -
APA
Nishio, M., Seto, T., Reck, M., Garon, E. B., Nishio, K., Kasahara, K., Nishino, K., Satouchi, M., Yoh, K., Hayashi, H., Sakai, K., Enatsu, S., Matsui, T., Varughese, S. C., Carlsen, M., Visseren-Grul, C., & Nakagawa, K. (2025). RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC. JTO Clinical and Research Reports. https://doi.org/10.1016/j.jtocrr.2025.100912
Source records
- crossref · retrieved 2026-09-26T02:40:33.755Z